Sun Pharma’s Q4FY22 Quarter Results
- 30 May 2022
- Sun Pharma’s consolidated revenues for the quarter ended March (Q4FY22) were down 7% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 11%.
- Its expenses for the quarter were down 2% QoQ and up 9% YoY
- The company reported a net loss of Rs 2,277 crore in Q4FY22 as against a net profit of Rs 894 crore in Q4FY21.
Sun Pharma’s Financial Statements for Q4FY22:
(Rs, crores)
Total Income
Q4FY21
8,634
Q3FY22
10,296
Q4FY22
9,560
QoQ (%)
-7%
YoY (%)
11%
(Rs, crores)
Total Expenses
Q4FY21
7,058
Q3FY22
7,829
Q4FY22
7,700
QoQ (%)
-2%
YoY (%)
9%
(Rs, crores)
Profit before tax
Q4FY21
903
Q3FY22
2,466
Q4FY22
-2,076
QoQ (%)
-
YoY (%)
-
(Rs, crores)
Tax
Q4FY21
55
Q3FY22
335
Q4FY22
147
QoQ (%)
-56%
YoY (%)
167
(Rs, crores)
Profit after tax
Q4FY21
894
Q3FY22
2,059
Q4FY22
-2,277
QoQ (%)
-
YoY (%)
-
(Rs, crores)
Earnings per share
Q4FY21
3.7
Q3FY22
8.6
Q4FY22
-
QoQ (%)
YoY (%)
| (Rs, crores) | Q4FY21 | Q3FY22 | Q4FY22 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
| Total Income | 8,634 | 10,296 | 9,560 | -7% | 11% |
| Total Expenses | 7,058 | 7,829 | 7,700 | -2% | 9% |
| Profit before tax | 903 | 2,466 | -2,076 | - | - |
| Tax | 55 | 335 | 147 | -56% | 167 |
| Profit after tax | 894 | 2,059 | -2,277 | - | - |
| Earnings per share | 3.7 | 8.6 | - |
Data Source: BSE, Company announcements
Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
